An analysis of drug development programs from the past 14 years has found that clinical trials for breast cancer are more successful if they include a validated biomarker, in this case HER2. Currently there is a very high clinical trial failure rate, leading to increased costs, both of which were mitigated by including a biomarker in the clinical trial. While this study is limited in scope, it does indicate that the inclusion of biomarkers in clinical research can improve the success rate.